Legal & General Group
ALLO icon

Legal & General Group’s Allogene Therapeutics ALLO Stock Holding History

Legal & General Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.5K Buy
25,743
+11,941
+87% +$26.2K ﹤0.01% 2744
2026
Q1 		$33.7K Hold
13,802
– – ﹤0.01% 2787
2025
Q4 		$18.9K Hold
13,802
– – ﹤0.01% 3053
2025
Q3 		$17.1K Hold
13,802
– – ﹤0.01% 3108
2025
Q2 		$15.6K Buy
13,802
+2,362
+21% +$3.14K ﹤0.01% 3109
2025
Q1 		$16.7K Sell
11,440
-100,795
-90% -$190K ﹤0.01% 3009
2024
Q4 		$239K Hold
112,235
– – ﹤0.01% 2645
2024
Q3 		$314K Buy
112,235
+1,563
+1% +$4.17K ﹤0.01% 2603
2024
Q2 		$258K Buy
110,672
+15,810
+17% +$46.6K ﹤0.01% 2632
2024
Q1 		$424K Buy
94,862
+12,706
+15% +$53K ﹤0.01% 2491
2023
Q4 		$264K Buy
82,156
+847
+1% +$2.4K ﹤0.01% 2656
2023
Q3 		$258K Buy
81,309
+4,103
+5% +$18K ﹤0.01% 2663
2023
Q2 		$384K Hold
77,206
– – ﹤0.01% 2543
2023
Q1 		$381K Buy
77,206
+2,682
+4% +$17.2K ﹤0.01% 2390
2022
Q4 		$469K Buy
74,524
+1,382
+2% +$12.8K ﹤0.01% 2354
2022
Q3 		$790K Sell
73,142
-2,230
-3% -$30.3K ﹤0.01% 2219
2022
Q2 		$859K Buy
75,372
+13,231
+21% +$117K ﹤0.01% 2213
2022
Q1 		$566K Buy
62,141
+112
+0.2% +$1.17K ﹤0.01% 2361
2021
Q4 		$926K Hold
62,029
– – ﹤0.01% 2254
2021
Q3 		$1.59M Buy
62,029
+25,261
+69% +$600K ﹤0.01% 2119
2021
Q2 		$959K Sell
36,768
-498
-1% -$14.2K ﹤0.01% 2219
2021
Q1 		$1.32M Buy
37,266
+10,039
+37% +$339K ﹤0.01% 2123
2020
Q4 		$687K Sell
27,227
-52
-0.2% -$1.7K ﹤0.01% 2194
2020
Q3 		$1.03M Sell
27,279
-1,483
-5% -$55.9K ﹤0.01% 2016
2020
Q2 		$1.23M Buy
28,762
+3,289
+13% +$119K ﹤0.01% 1914
2020
Q1 		$496K Sell
25,473
-1,703
-6% -$40.6K ﹤0.01% 2067
2019
Q4 		$706K Buy
27,176
+7,729
+40% +$213K ﹤0.01% 2152
2019
Q3 		$530K Hold
19,447
– – ﹤0.01% 2158
2019
Q2 		$522K Sell
19,447
-82,583
-81% -$2.3M ﹤0.01% 2135
2019
Q1 		$2.95M Buy
102,030
+98,721
+2,983% +$2.86M ﹤0.01% 1500
2018
Q4 		$89K Buy
+3,309
New +$87.9K ﹤0.01% 2489

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Legal & General Group's ALLO Position: Q2 2026 in Review

Legal & General Group increased its Allogene Therapeutics (ALLO) stake by 87% in Q2 2026, buying an estimated $26.2K and bringing the position to 25,743 shares worth $53.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2744.

Legal & General Group first reported a position in ALLO in Q4 2018 and has held it in 31 quarters since. The position peaked at $2.95M in Q1 2019. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Legal & General Group held 25,743 shares of Allogene Therapeutics worth $53.5K as of Q2 2026.
  • Legal & General Group bought 11,941 Allogene Therapeutics shares in Q2 2026, an estimated $26.2K.
  • Allogene Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2744 holding.
  • Legal & General Group first reported a position in Allogene Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • Legal & General Group's Allogene Therapeutics position peaked at $2.95M in Q1 2019.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.